Harvard Bioscience (HBIO) 2.81 $HBIO Harvard Bioscience

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 11:15 AM

Harvard Bioscience (HBIO) 2.81 $HBIO

Harvard Bioscience to Attend The Benchmark Company, LLC One-on-One Conference in Milwaukee, Wisconsin on June 2, 2016
GlobeNewswire - Tue May 31, 5:30AM CDT
Harvard Bioscience, Inc. (NASDAQ:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will participate in The Benchmark Company, LLC One-on-One Conference at The Pfister Hotel in Milwaukee, Wisconsin on Thursday, June 2, 2016.
HBIO: 2.81 (+0.01)

Harvard Bioscience reports 1Q loss
Automated Insights - Thu May 12, 5:15AM CDT
HOLLISTON, Mass. (AP) _ Harvard Bioscience Inc. (HBIO) on Thursday reported a loss of $636,000 in its first quarter.
HBIO: 2.81 (+0.01)

Harvard Bioscience Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 12, 5:00AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company"

, a global developer, manufacturer and marketer of a broad range of solutions to advance life science, reported its financial results for the three months ended March 31, 2016.
HBIO: 2.81 (+0.01)

Harvard Bioscience Regains Compliance with NASDAQ's Continued Listing Requirements
GlobeNewswire - Wed May 04, 3:16PM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company"

, a global developer, manufacturer and marketer of a broad range of solutions to advance life science, announced today that it received written notification from NASDAQ (the "Notice"

stating the Company has regained compliance with NASDAQ's Listing Rule 5250(c)(1) and the matter is now closed.
HBIO: 2.81 (+0.01)

Harvard Bioscience Reports Fourth Quarter and Year-End 2015 Results, Preliminary First Quarter 2016 Revenues and 2016 Financial Guidance
GlobeNewswire - Fri Apr 29, 3:45PM CDT
Reports Results of Embezzlement Investigation
HBIO: 2.81 (+0.01)

Harvard Bioscience Delays Filing of Annual Report on Form 10-K and Announces Preliminary Unaudited Fourth Quarter and Fiscal Year 2015 Revenue
GlobeNewswire - Mon Mar 28, 3:15PM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company"

, a global developer, manufacturer and marketer of a broad range of solutions to advance life science, today announced that the filing of its Annual Report on Form 10-K for the year ended December 31, 2015 (the "Form 10-K"

would not occur prior to the extended March 30, 2016 deadline, and also announced preliminary unaudited revenue for the three and twelve months ended December 31, 2015.
HBIO: 2.81 (+0.01)

Harvard Bioscience Receives NASDAQ Delinquency Notice
GlobeNewswire - Thu Mar 17, 3:45PM CDT
On March 16, 2016, Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company"

, a global developer, manufacturer and marketer of a broad range of solutions to advance life science, received a notice from NASDAQ (the "Notice"

stating the Company is not in compliance with Listing Rule 5250(c)(1) for continued listing because it has not yet filed its Annual Report on Form 10-K (the "Form 10-K"

for the year ended December 31, 2015 by the due date of March 15, 2016.
HBIO: 2.81 (+0.01)

Harvard Bioscience Announces Delay in Filing Form 10-K
GlobeNewswire - Mon Mar 14, 6:17PM CDT
-- Reports Delay is Result of Forensic Investigation Following Minor Employee Theft
HBIO: 2.81 (+0.01)

Investors Flock to Pressure BioSciences as Its Patented PCT Platform Goes Mainstream
ACCESSWIRE - Fri Jan 15, 8:35AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 15, 2016 / Pressure BioSciences Inc. (OTCQB: PBIO) just announced that it exceeded its $5 million fundraising goal and approved the opening of an additional $1.25 million over-subscription amount in its PIPE offering. With growing revenue, a new multi-national partner (see below), and a potential up-listing in the near future, accredited investors have been flocking into the company's stock through the private offering, and retail investors have been flocking into the company's stock in the open market. Both of these may be bullish signs for individual investors for the coming year.
HBIO: 2.81 (+0.01), TMO: 152.87 (+0.18), HTGM: 2.73 (+0.02), DHR: 80.32 (-0.54), WAT: 145.75 (-0.78)

BUYINS.NET: RAIL, APU, HBIO, MMP, AMKR, STLD Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri Dec 18, 6:40AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Freightcar America Inc (NASDAQ:RAIL), Amerigas Partners LP (NYSE:APU), Harvard Bioscience Inc (NASDAQ:HBIO), Magellan Midstream Partners LP (NYSE:MMP), Amkor Technology Inc (NASDAQ:AMKR), Steel Dynamics Inc (NASDAQ:STLD) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
STLD: 26.87 (+0.23), AMKR: 5.99 (+0.03), HBIO: 2.81 (+0.01), APU: 48.00 (+0.09), RAIL: 14.93 (+0.30), MMP: 74.85 (+0.71)

Pressure BioSciences Cleans Up Balance Sheet with Successful PIPE Financing
ACCESSWIRE - Wed Dec 16, 8:20AM CST
Improved Balance Sheet Paves Way for Increased Revenue, Potential Uplisting and Stronger Shareholder Value
HBIO: 2.81 (+0.01), NSTG: 13.50 (+0.51)

Falling Earnings Estimates Signal Weakness Ahead for Harvard Bioscience (HBIO)
Zacks Equity Research - Zacks Investment Research - Wed Nov 25, 7:31AM CST
It may not be a good decision to keep Harvard Bioscience (HBIO) stock in your portfolio anymore.
HBIO: 2.81 (+0.01), BRKR: 24.11 (+0.43)

Strong Revenue Growth in the $6 Billion Biological Sample Preparation Market
ACCESSWIRE - Fri Nov 13, 8:20AM CST
REDONDO BEACH, CA / ACCESSWIRE / November 13, 2015 / Biological sample preparation may sound like a commoditized industry, but the $6 billion market serving 500,000 scientists across 80,000 research labs is ripe for innovation. With traditional technologies like blenders or freeze-thaw cycles employing mechanical disruption, current sample preparation methods are a bottleneck for researchers in terms of the number of samples that can be prepared at any given time and the reproducibility of the results generated by these processes.
HBIO: 2.81 (+0.01), NSTG: 13.50 (+0.51)

Harvard Bioscience Reports Third Quarter 2015 Financial Results and Updates Outlook for Full-Year 2015
GlobeNewswire - Thu Oct 29, 5:30AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, reported financial results for the three and nine months ended September 30, 2015.
HBIO: 2.81 (+0.01)

Harvard Bioscience to Showcase Array of New Products at Society for Neuroscience 2015 Annual Meeting in Chicago on October 18-21
GlobeNewswire - Fri Oct 16, 9:00AM CDT
Harvard Bioscience, Inc. (NASDAQ:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will feature new and existing products from its expanded portfolio of brands at the Society for Neuroscience 2015 Annual Meeting at Chicago's McCormick Place Convention Center on October 18-21. This year, for the first time, the Company's Harvard Apparatus booth will incorporate a host of instruments from Harvard Bioscience's three recently acquired companies--HEKA Elektronik, Multi Channel Systems and Triangle BioSystems International--directly alongside those from its established brands. There will also be two dedicated workstations in the Harvard Apparatus booth for scheduled one-on-one product demonstrations and training sessions.
HBIO: 2.81 (+0.01)

Harvard Bioscience Schedules Third Quarter 2015 Conference Call for October 29 at 8:30 AM ET
GlobeNewswire - Thu Oct 15, 3:05PM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its third quarter 2015 before market trading hours on Thursday, October 29, 2015. A conference call to discuss the company's third quarter 2015 financial results and its operations is scheduled for that same date at 8:30 AM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
HBIO: 2.81 (+0.01)

BUYINS.NET: HBIO SqueezeTrigger Price is $4.53. There is $6,266,352 That Short Sellers Still Need To Cover.
M2 - Fri Sep 11, 12:06PM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Harvard Bioscience Inc (NASDAQ:HBIO) in real time and just received an alert that HBIO is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 1374200 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $4.53. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
HBIO: 2.81 (+0.01)

Harvard Bioscience posts 2Q profit
Automated Insights - Thu Jul 30, 5:42AM CDT
HOLLISTON, Mass. (AP) _ Harvard Bioscience Inc. (HBIO) on Thursday reported second-quarter net income of $349,000.
HBIO: 2.81 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Power Knot MEA Wins THE BIZZ 2026 for Excellence

Setting the Pace in Waste Management If there's one thing that sticks in my craw, it's how businesses handle food waste. Power Knot Middle East (PKME) seems to have cracked the code by not just leading the charge in organic waste management but also bagging THE BIZZ 2026 award. They’re not just playing industry games; PKME's pulling the strings with real leadership and...

Monteverde's Equity Alert: Scrutinizing Recent M&A Deals

Diving Into M&A Deals Under Monteverde's Lens Wall Street’s not just about suits and skyscrapers; it’s about the nitty-gritty of deals and whether those numbers add up in the investor's favor. So, when Monteverde & Associates PC throws its weight into scrutinizing mergers and acquisitions, you better believe it's worth a second look. See, they’re digging into four...

Black Culture Icon: Plastic-Covered Couch Takes Stage

A Plastic-Laden Piece of History Makes Art Who'd have thought a plastic-covered couch would turn into a cultural artifact? This iconic staple in Black households has done just that, debuting at Brooklyn's CultureCon in a fresh guise. It's more than just an upcycled furniture piece; it's a living archive that encapsulates Black culture, joy, and resilience. The Heart...

ARTBOX Brings Korean Lifestyle Magic to LA Pop-Up

ARTBOX: From Seoul to La-La Land Here's what caught my eye. It's 2026, and Korean lifestyle retailer ARTBOX is making a splash in the U.S.—kicking things off with a pop-up in LA. Now, usually, I'd be skeptical about pop-ups, but you've got to admire the audacity and timing here. They've picked Melrose Avenue, a hotspot for all things trendy, to introduce their mix of...

Monster Energy Dominates Skateboard Podium at SLS Paris

Monster Energy's Skateboard Triumph Hold the front page, because Monster Energy just pulled off a clean sweep in Paris. The company's team riders dominated the Men's Skateboard Street competition at the SLS Paris 2026, with the iconic Nyjah Huston snagging the top spot. It's a story filled with triumph, grit, and a dash of raw talent in a vibrant field of international...

Monteverde Probes Four Key M&A Deals for Fairness

Examining the Intricacies of Pending M&A The merger and acquisition landscape can be vicious, especially when the sharks—those pesky class action lawyers—start circling. And let me tell you, Monteverde & Associates PC is diving headfirst into the fray, launching inquiries into a handful of these deals. This isn't your first stroll down Wall Street if you’ve seen one...

SiBionics and PharmaSens Unveil Diabetes Tech at EASD

Shaking Up Diabetes Care: New Tech Unveiled Imagine a world where managing diabetes isn't a juggling act with multiple devices. That's precisely the future SiBionics and PharmaSens are pitching at the European Association for the Study of Diabetes (EASD) 2026 in Milan. Now, let me tell you, these guys aren't just playing around with ideas; they're aiming to radically...

Unpacking Monteverde's M&A Investigations Hold your horses, folks! The M&A Class Action Firm is stirring the pot with its latest inquiries into some high-profile mergers. We're looking at Lisata Therapeutics, Flag Ship Acquisition Corporation, Baldwin Insurance Group, and ACV Auctions. So what's got Juan Monteverde's legal eagles swooping in on these deals? Well, are we...

Blokees Unveils 90+ New Wonders at Shanghai Fest

A Grand Stage for New Arrivals Picture this: In the bustling and glittering chaos that was the Wonder Festival Shanghai 2026, held from October 3 to 4, Blokees laid down a major marker. More than 500 products, an artillery of imagination and craftsmanship, were on deck across their key lines—Blokees Model Kits and BLOKEES WHEELS. With 90 brand-new creations making their...

Lawsuit Highlights Inaction in School Bus Tragedy

Seeking Justice Amid Heartbreak Tragedy rarely arrives whispered on the wind—more often, it's the train wreck some saw coming long before it hits. The tragic death of Jenna Menias, a 6-year-old from Frankfort, Illinois, falls squarely in this camp. The family's legal lions, Corboy & Demetrio, have slapped two school districts—District 210 and 157-C—with a wrongful...